EXABS-231-ABCL The Treatment of Primary and Secondary CNS Lymphoma
Saved in:
| Published in | Clinical lymphoma, myeloma and leukemia Vol. 23; pp. S119 - S122 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier Inc
01.09.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Author | Cwynarski, Kate Khwaja, Jahanzaib |
|---|---|
| Author_xml | – sequence: 1 givenname: Jahanzaib surname: Khwaja fullname: Khwaja, Jahanzaib organization: University College London Hospitals, United Kingdom – sequence: 2 givenname: Kate surname: Cwynarski fullname: Cwynarski, Kate email: kate.cwynarski@nhs.net organization: University College London Hospitals, United Kingdom |
| BookMark | eNqNUE1Lw0AUXKSCbfUnCDnqYfXtbnaTHkTaUD8gqJAK3pbN5oWuNhvZFKH_3qYtHrzo6b03jxlmZkQGvvVIyDmDKwZMXRecSU65knDBxSWAEDFNj8jwAKvJ4GeXcEJGXfcOkACwyZDM5m_TWUG5YHQ6y_JoscRoEdCsG_TrqK2jl-AaEzaR8VVUoG191V_ZUxHlm-Zz2TbmlBzXZtXh2WGOyevdfJE90Pz5_jGb5tRyECktRYyG8QQrlZRcsVhJTI0AMJgYKWVZipLVTJhJzOMtEosyTRRu_4LVtkrFmMi9rg1t1wWs9efem2ag-yL0rgjdp9Rc6F0Ruufd7nm4NfflMOjOOvQWKxfQrnXVuj8Vbn4p2JXzzprVB27-wf8GZ7B2wg |
| Cites_doi | 10.1007/s11060-008-9716-0 10.1182/blood-2018-02-835496 10.3324/haematol.2014.108472 10.1016/j.bbmt.2004.09.009 10.1016/j.ejca.2019.05.024 10.1182/bloodadvances.2017014845 10.1016/j.ejca.2018.01.073 10.1016/S0140-6736(09)61416-1 10.1038/leu.2016.334 10.1016/S2352-3026(20)30366-5 10.1182/bloodadvances.2020004106 10.1182/blood-2017-01-764209 10.1038/s41375-022-01582-5 10.1001/jamaoncol.2021.1074 10.1093/annonc/mdz032 10.1182/bloodadvances.2022008525 10.1016/1040-8428(92)90092-5 10.1111/bjh.18539 10.1093/neuonc/now033 10.1200/JCO.2002.11.013 10.1182/blood-2022-165256 10.1182/blood-2018-09-875732 10.1182/blood.2021014738 10.1200/JCO.2015.61.1236 10.1016/j.annonc.2020.05.016 10.1158/2159-8290.CD-17-0613 10.1200/JCO.2021.39.15_suppl.7506 10.1200/JCO.2013.50.4910 10.3324/haematol.2022.281640 10.1016/j.ccell.2017.04.012 10.1182/bloodadvances.2022007011 |
| ContentType | Journal Article |
| Copyright | 2023 Elsevier Inc. |
| Copyright_xml | – notice: 2023 Elsevier Inc. |
| DBID | AAYXX CITATION |
| DOI | 10.1016/S2152-2650(23)00334-8 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2152-2669 |
| EndPage | S122 |
| ExternalDocumentID | 10_1016_S2152_2650_23_00334_8 S2152265023003348 |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1P~ 1~. 4.4 457 4G. 53G 5VS 6PF 7-5 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV C45 CAG COF DU5 EBS EFJIC EFKBS EJD EMOBN F5P FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MET MO0 O-L O9- OAUVE OC~ OO- OVD P-8 P-9 PC. Q38 ROL SDF SEL SES SPCBC SSH SSZ T5K TEORI XH2 Z5R ~G- AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW EFLBG EMB LCYCR SV3 AAYXX AGRNS CITATION |
| ID | FETCH-LOGICAL-c2038-b34ea127ed67b261465e8a300ae7a555bb3b1f13a94247a543b876e00a31fcd83 |
| IEDL.DBID | .~1 |
| ISSN | 2152-2650 |
| IngestDate | Tue Jul 01 01:03:14 EDT 2025 Fri Feb 23 02:38:07 EST 2024 Tue Aug 26 20:09:49 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | neurocognitive Chemoimmunotherapy CAR-T transplantation BTKi |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2038-b34ea127ed67b261465e8a300ae7a555bb3b1f13a94247a543b876e00a31fcd83 |
| OpenAccessLink | https://doi.org/10.1016/s2152-2650(23)00334-8 |
| ParticipantIDs | crossref_primary_10_1016_S2152_2650_23_00334_8 elsevier_sciencedirect_doi_10_1016_S2152_2650_23_00334_8 elsevier_clinicalkey_doi_10_1016_S2152_2650_23_00334_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | September 2023 2023-09-00 |
| PublicationDateYYYYMMDD | 2023-09-01 |
| PublicationDate_xml | – month: 09 year: 2023 text: September 2023 |
| PublicationDecade | 2020 |
| PublicationTitle | Clinical lymphoma, myeloma and leukemia |
| PublicationYear | 2023 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Scordo, Wang, Ahn (bib6) Jul 1 2021; 7 Batchelor, Giri, Ruppert (bib4) 2021; 39 Lesueur, Damaj, Hoang-Xuan (bib11) Aug 23 2022; 6 Khwaja, Kirkwood, Isbell (bib20) Oct 27 2022 Grommes, Pastore, Palaskas (bib24) 2017; 7 Ferreri, Cwynarski, Pulczynski (bib13) Jul 2022; 36 Wiebe, Smith, DeGregorio, Rappeport (bib5) Nov 1992; 13 DeAngelis, Seiferheld, Schold, Fisher, Schultz (bib1) Dec 15 2002; 20 Pulczynski, Kuittinen, Erlanson (bib8) Apr 2015; 100 Frigault, Dietrich, Gallagher (bib32) Apr 14 2022; 139 Ghesquieres, Chevrier, Laadhari (bib30) 2019; 30 El-Galaly, Cheah, Bendtsen (bib14) Apr 2018; 93 Ferreri, Donadoni, Cabras (bib15) Nov 20 2015; 33 Langner-Lemercier, Houillier, Soussain (bib12) Sep 2016; 18 Grommes, Tang, Wolfe (bib25) Jan 2019; 133 Correa, Rocco-Donovan, DeAngelis (bib10) Feb 2009; 91 Lionakis, Dunleavy, Roschewski (bib27) 2017; 31 Cwynarski, Cummin, Osborne (bib18) Jan 2023; 200 Siddiqi, Wang, Blanchard (bib33) Oct 26 2021; 5 Ferreri, Doorduijn, Re (bib17) Feb 2021; 8 Ferreri, Doorduijn, Re (bib16) Feb 2021; 8 Cook, Dorris, Makambi (bib22) Jan 10 2023; 7 Ferreri, Cwynarski, Pulczynski (bib3) May 13 2022 McMillan, Phillips, Kirkwood (bib19) 2020; 31 Rubenstein, Geng, Fraser (bib28) 2018; 2 Nayak, Iwamoto, LaCasce (bib31) Jun 8 2017; 129 Morris, Correa, Yahalom (bib9) Nov 01 2013; 31 Kasamon, Jones, Piantadosi (bib23) Feb 2005; 11 Fritsch, Kasenda, Schorb (bib7) Apr 2017; 31 Jacobson, Falvey, Bouvier (bib21) 2022; 140 Tun, Johnston, DeAngelis (bib29) 2018; 132 Soussain, Choquet, Blonski (bib26) Aug 2019; 117 Ferreri, Reni, Foppoli (bib2) Oct 31 2009; 374 Rubenstein (10.1016/S2152-2650(23)00334-8_bib28) 2018; 2 Scordo (10.1016/S2152-2650(23)00334-8_bib6) 2021; 7 Cook (10.1016/S2152-2650(23)00334-8_bib22) 2023; 7 Nayak (10.1016/S2152-2650(23)00334-8_bib31) 2017; 129 Morris (10.1016/S2152-2650(23)00334-8_bib9) 2013; 31 Ferreri (10.1016/S2152-2650(23)00334-8_bib16) 2021; 8 Ferreri (10.1016/S2152-2650(23)00334-8_bib13) 2022; 36 Khwaja (10.1016/S2152-2650(23)00334-8_bib20) 2022 Fritsch (10.1016/S2152-2650(23)00334-8_bib7) 2017; 31 Frigault (10.1016/S2152-2650(23)00334-8_bib32) 2022; 139 Grommes (10.1016/S2152-2650(23)00334-8_bib25) 2019; 133 Lesueur (10.1016/S2152-2650(23)00334-8_bib11) 2022; 6 Ghesquieres (10.1016/S2152-2650(23)00334-8_bib30) 2019; 30 El-Galaly (10.1016/S2152-2650(23)00334-8_bib14) 2018; 93 Tun (10.1016/S2152-2650(23)00334-8_bib29) 2018; 132 Kasamon (10.1016/S2152-2650(23)00334-8_bib23) 2005; 11 DeAngelis (10.1016/S2152-2650(23)00334-8_bib1) 2002; 20 Wiebe (10.1016/S2152-2650(23)00334-8_bib5) 1992; 13 Cwynarski (10.1016/S2152-2650(23)00334-8_bib18) 2023; 200 Ferreri (10.1016/S2152-2650(23)00334-8_bib17) 2021; 8 Grommes (10.1016/S2152-2650(23)00334-8_bib24) 2017; 7 Jacobson (10.1016/S2152-2650(23)00334-8_bib21) 2022; 140 Ferreri (10.1016/S2152-2650(23)00334-8_bib3) 2022 Ferreri (10.1016/S2152-2650(23)00334-8_bib15) 2015; 33 Soussain (10.1016/S2152-2650(23)00334-8_bib26) 2019; 117 Ferreri (10.1016/S2152-2650(23)00334-8_bib2) 2009; 374 Batchelor (10.1016/S2152-2650(23)00334-8_bib4) 2021; 39 Langner-Lemercier (10.1016/S2152-2650(23)00334-8_bib12) 2016; 18 Pulczynski (10.1016/S2152-2650(23)00334-8_bib8) 2015; 100 Siddiqi (10.1016/S2152-2650(23)00334-8_bib33) 2021; 5 McMillan (10.1016/S2152-2650(23)00334-8_bib19) 2020; 31 Lionakis (10.1016/S2152-2650(23)00334-8_bib27) 2017; 31 Correa (10.1016/S2152-2650(23)00334-8_bib10) 2009; 91 |
| References_xml | – volume: 93 start-page: 57 year: Apr 2018 end-page: 68 ident: bib14 article-title: Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma publication-title: Eur J Cancer – volume: 39 start-page: 7506 year: 2021 ident: bib4 article-title: Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance) publication-title: Journal of Clinical Oncology – year: May 13 2022 ident: bib3 article-title: Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial publication-title: Leukemia – volume: 5 start-page: 4059 year: Oct 26 2021 end-page: 4063 ident: bib33 article-title: CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma publication-title: Blood Adv – volume: 8 start-page: e110 year: Feb 2021 end-page: e121 ident: bib16 article-title: MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial publication-title: Lancet Haematol – volume: 11 start-page: 93 year: Feb 2005 end-page: 100 ident: bib23 article-title: High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement publication-title: Biol Blood Marrow Transplant – volume: 31 start-page: 833 year: 2017 end-page: 843.e5 ident: bib27 article-title: Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma publication-title: Cancer Cell – volume: 20 start-page: 4643 year: Dec 15 2002 end-page: 4648 ident: bib1 article-title: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10 publication-title: J Clin Oncol – volume: 129 start-page: 3071 year: Jun 8 2017 end-page: 3073 ident: bib31 article-title: PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma publication-title: Blood – volume: 117 start-page: 121 year: Aug 2019 end-page: 130 ident: bib26 article-title: Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network publication-title: Eur J Cancer – volume: 18 start-page: 1297 year: Sep 2016 end-page: 1303 ident: bib12 article-title: Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network publication-title: Neuro Oncol – volume: 132 start-page: 2240 year: 2018 end-page: 2248 ident: bib29 article-title: Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma publication-title: Blood – volume: 7 start-page: 993 year: Jul 1 2021 end-page: 1003 ident: bib6 article-title: Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant publication-title: JAMA Oncol – volume: 140 start-page: 1060 year: 2022 end-page: 1061 ident: bib21 article-title: A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL) publication-title: Blood – volume: 30 start-page: 621 year: 2019 end-page: 628 ident: bib30 article-title: Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)† publication-title: Ann Oncol – volume: 200 start-page: 160 year: Jan 2023 end-page: 169 ident: bib18 article-title: Management of secondary central nervous system lymphoma publication-title: Br J Haematol – volume: 139 start-page: 2306 year: Apr 14 2022 end-page: 2315 ident: bib32 article-title: Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial publication-title: Blood – volume: 133 start-page: 436 year: Jan 2019 end-page: 445 ident: bib25 article-title: Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma publication-title: Blood – volume: 374 start-page: 1512 year: Oct 31 2009 end-page: 1520 ident: bib2 article-title: High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial publication-title: Lancet – volume: 31 start-page: 3971 year: Nov 01 2013 end-page: 3979 ident: bib9 article-title: Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome publication-title: J Clin Oncol – volume: 7 start-page: 32 year: Jan 10 2023 end-page: 39 ident: bib22 article-title: Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients publication-title: Blood Adv – volume: 13 start-page: 241 year: Nov 1992 end-page: 270 ident: bib5 article-title: Pharmacology of agents used in bone marrow transplant conditioning regimens publication-title: Crit Rev Oncol Hematol – volume: 6 start-page: 4807 year: Aug 23 2022 end-page: 4815 ident: bib11 article-title: Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study publication-title: Blood Adv – volume: 36 start-page: 1870 year: Jul 2022 end-page: 1878 ident: bib13 article-title: Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial publication-title: Leukemia – volume: 100 start-page: 534 year: Apr 2015 end-page: 540 ident: bib8 article-title: Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group publication-title: Haematologica – year: Oct 27 2022 ident: bib20 article-title: International multicentre retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma publication-title: Haematologica – volume: 2 start-page: 1595 year: 2018 end-page: 1607 ident: bib28 article-title: Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma publication-title: Blood Adv – volume: 31 start-page: 846 year: Apr 2017 end-page: 852 ident: bib7 article-title: High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) publication-title: Leukemia – volume: 7 start-page: 1018 year: 2017 end-page: 1029 ident: bib24 article-title: Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma publication-title: Cancer Discov – volume: 8 start-page: e110 year: Feb 2021 end-page: e121 ident: bib17 article-title: MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial publication-title: Lancet Haematol – volume: 33 start-page: 3903 year: Nov 20 2015 end-page: 3910 ident: bib15 article-title: High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial publication-title: J Clin Oncol – volume: 31 start-page: 1251 year: 2020 end-page: 1259 ident: bib19 article-title: Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOXM/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial publication-title: Ann Oncol – volume: 91 start-page: 315 year: Feb 2009 end-page: 321 ident: bib10 article-title: Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy publication-title: J Neurooncol – volume: 91 start-page: 315 issue: 3 year: 2009 ident: 10.1016/S2152-2650(23)00334-8_bib10 article-title: Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy publication-title: J Neurooncol doi: 10.1007/s11060-008-9716-0 – volume: 132 start-page: 2240 issue: 21 year: 2018 ident: 10.1016/S2152-2650(23)00334-8_bib29 article-title: Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma publication-title: Blood doi: 10.1182/blood-2018-02-835496 – volume: 100 start-page: 534 issue: 4 year: 2015 ident: 10.1016/S2152-2650(23)00334-8_bib8 article-title: Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group publication-title: Haematologica doi: 10.3324/haematol.2014.108472 – volume: 11 start-page: 93 issue: 2 year: 2005 ident: 10.1016/S2152-2650(23)00334-8_bib23 article-title: High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2004.09.009 – volume: 117 start-page: 121 year: 2019 ident: 10.1016/S2152-2650(23)00334-8_bib26 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2019.05.024 – volume: 2 start-page: 1595 issue: 13 year: 2018 ident: 10.1016/S2152-2650(23)00334-8_bib28 article-title: Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma publication-title: Blood Adv doi: 10.1182/bloodadvances.2017014845 – volume: 93 start-page: 57 year: 2018 ident: 10.1016/S2152-2650(23)00334-8_bib14 article-title: Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma publication-title: Eur J Cancer doi: 10.1016/j.ejca.2018.01.073 – volume: 374 start-page: 1512 issue: 9700 year: 2009 ident: 10.1016/S2152-2650(23)00334-8_bib2 article-title: High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(09)61416-1 – volume: 31 start-page: 846 issue: 4 year: 2017 ident: 10.1016/S2152-2650(23)00334-8_bib7 article-title: High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) publication-title: Leukemia doi: 10.1038/leu.2016.334 – volume: 8 start-page: e110 issue: 2 year: 2021 ident: 10.1016/S2152-2650(23)00334-8_bib16 article-title: MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial publication-title: Lancet Haematol doi: 10.1016/S2352-3026(20)30366-5 – volume: 5 start-page: 4059 issue: 20 year: 2021 ident: 10.1016/S2152-2650(23)00334-8_bib33 article-title: CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma publication-title: Blood Adv doi: 10.1182/bloodadvances.2020004106 – volume: 129 start-page: 3071 issue: 23 year: 2017 ident: 10.1016/S2152-2650(23)00334-8_bib31 article-title: PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma publication-title: Blood doi: 10.1182/blood-2017-01-764209 – year: 2022 ident: 10.1016/S2152-2650(23)00334-8_bib3 article-title: Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial publication-title: Leukemia doi: 10.1038/s41375-022-01582-5 – volume: 36 start-page: 1870 issue: 7 year: 2022 ident: 10.1016/S2152-2650(23)00334-8_bib13 article-title: Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial publication-title: Leukemia doi: 10.1038/s41375-022-01582-5 – volume: 7 start-page: 993 issue: 7 year: 2021 ident: 10.1016/S2152-2650(23)00334-8_bib6 article-title: Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2021.1074 – volume: 30 start-page: 621 issue: 4 year: 2019 ident: 10.1016/S2152-2650(23)00334-8_bib30 publication-title: Ann Oncol doi: 10.1093/annonc/mdz032 – volume: 7 start-page: 32 issue: 1 year: 2023 ident: 10.1016/S2152-2650(23)00334-8_bib22 article-title: Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients publication-title: Blood Adv doi: 10.1182/bloodadvances.2022008525 – volume: 13 start-page: 241 issue: 3 year: 1992 ident: 10.1016/S2152-2650(23)00334-8_bib5 article-title: Pharmacology of agents used in bone marrow transplant conditioning regimens publication-title: Crit Rev Oncol Hematol doi: 10.1016/1040-8428(92)90092-5 – volume: 200 start-page: 160 issue: 2 year: 2023 ident: 10.1016/S2152-2650(23)00334-8_bib18 article-title: Management of secondary central nervous system lymphoma publication-title: Br J Haematol doi: 10.1111/bjh.18539 – volume: 18 start-page: 1297 issue: 9 year: 2016 ident: 10.1016/S2152-2650(23)00334-8_bib12 article-title: Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network publication-title: Neuro Oncol doi: 10.1093/neuonc/now033 – volume: 8 start-page: e110 issue: 2 year: 2021 ident: 10.1016/S2152-2650(23)00334-8_bib17 article-title: MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial publication-title: Lancet Haematol doi: 10.1016/S2352-3026(20)30366-5 – volume: 20 start-page: 4643 issue: 24 year: 2002 ident: 10.1016/S2152-2650(23)00334-8_bib1 article-title: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10 publication-title: J Clin Oncol doi: 10.1200/JCO.2002.11.013 – volume: 140 start-page: 1060 issue: Supplement 1 year: 2022 ident: 10.1016/S2152-2650(23)00334-8_bib21 article-title: A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL) publication-title: Blood doi: 10.1182/blood-2022-165256 – volume: 133 start-page: 436 issue: 5 year: 2019 ident: 10.1016/S2152-2650(23)00334-8_bib25 article-title: Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma publication-title: Blood doi: 10.1182/blood-2018-09-875732 – volume: 139 start-page: 2306 issue: 15 year: 2022 ident: 10.1016/S2152-2650(23)00334-8_bib32 article-title: Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial publication-title: Blood doi: 10.1182/blood.2021014738 – volume: 33 start-page: 3903 issue: 33 year: 2015 ident: 10.1016/S2152-2650(23)00334-8_bib15 article-title: High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial publication-title: J Clin Oncol doi: 10.1200/JCO.2015.61.1236 – volume: 31 start-page: 1251 issue: 9 year: 2020 ident: 10.1016/S2152-2650(23)00334-8_bib19 article-title: Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOXM/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.05.016 – volume: 7 start-page: 1018 issue: 9 year: 2017 ident: 10.1016/S2152-2650(23)00334-8_bib24 article-title: Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-17-0613 – volume: 39 start-page: 7506 issue: 15_suppl year: 2021 ident: 10.1016/S2152-2650(23)00334-8_bib4 article-title: Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance) publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2021.39.15_suppl.7506 – volume: 31 start-page: 3971 issue: 31 year: 2013 ident: 10.1016/S2152-2650(23)00334-8_bib9 article-title: Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome publication-title: J Clin Oncol doi: 10.1200/JCO.2013.50.4910 – year: 2022 ident: 10.1016/S2152-2650(23)00334-8_bib20 article-title: International multicentre retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma publication-title: Haematologica doi: 10.3324/haematol.2022.281640 – volume: 31 start-page: 833 issue: 6 year: 2017 ident: 10.1016/S2152-2650(23)00334-8_bib27 article-title: Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.04.012 – volume: 6 start-page: 4807 issue: 16 year: 2022 ident: 10.1016/S2152-2650(23)00334-8_bib11 article-title: Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study publication-title: Blood Adv doi: 10.1182/bloodadvances.2022007011 |
| SSID | ssj0070019 |
| Score | 2.320001 |
| SourceID | crossref elsevier |
| SourceType | Index Database Publisher |
| StartPage | S119 |
| SubjectTerms | BTKi CAR-T Chemoimmunotherapy neurocognitive transplantation |
| Title | EXABS-231-ABCL The Treatment of Primary and Secondary CNS Lymphoma |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2152265023003348 https://dx.doi.org/10.1016/S2152-2650(23)00334-8 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NS8MwFA9jgngRP3F-jBw86CHb2iRtPXZlY-o2hG6wW0jbBHawGzIPXvzbfa8fU0EYeGyaF8ov6S-_R97LI-SWW7y2HNhPZ_C7CaktCwS3LEmtAbVgfVsUg5lMvdFcPC3kokGiOhcGwyor7i85vWDrqqVbodldL5fdGCuyuiAwQET3MJ8UM9iFj6u887kN88BjVZTA2Jlh7-8snnKEovHO5ffFICz4e3_6secMj8hhJRZpWH7PMWmY_ITsT6rj8FPSHyzCfsxAPLGwH40pzDmd1ZHjdGXpS3mXBNV5RmN0fTN8iqYxHX_ANK5e9RmZDwezaMSqoggsdXtATgkXRjuubzLPT8D9EZ40gQYItPG1lDJJeOJYh-sH4QpoETwBwjPwnjs2zQJ-Tpr5KjcXhIIvYaWVOnNSrMuXBuAMpqn0hcbjUr_XIp0aCrUuv1dtg8IQO4XYKZerAjsVtIhXA6bqxE6gIgXsvMsw2Br-mv3dppf_N70iB1g8vowYuybNzdu7uQGJsUnaxRpqk73w8Xk0_QI8mcS2 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NS8MwFH_MDdSL-InzMwcPeohbm6Stx21sdK4bwjbYLaRtAjvYDZkH_3tf-jEVBMFj074Qfkl_-T3yXh7AHTP22nJkP5Xi78aFMjTgzNA4MRrVgvFNXgxmPPHCOX9eiEUNelUujA2rLLm_4PScrcuWVolma71ctqa2IquLAgNFdNvmk-5Aw95OJerQ6AxH4aQiZHuyalWw_Z5ag69EnqKTvPHeZQ95PzT4fYv6tu0MDuGg1IukUwzpCGo6O4bdcXkifgLd_qLTnVLUT7TT7UUEp53MquBxsjLkpbhOgqgsJVPr_ab2qTeZkugDZ3L1qk5hPujPeiEt6yLQxG0jP8WMa-W4vk49P0YPiHtCBwpRUNpXQog4ZrFjHKaeuMuxhbMYOU_je-aYJA3YGdSzVabPgaA7YYQRKnUSW5ovCdAfTBLhc2VPTP12Ex4rKOS6GK_cxoVZ7KTFTrpM5tjJoAleBZiscjuRjSQS9F-GwdbwxwL42_Ti_6a3sBfOxpGMhpPRJezbWvJFANkV1Ddv7_oaFccmvilX1CcrgMdn |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EXABS-231-ABCL+The+Treatment+of+Primary+and+Secondary+CNS+Lymphoma&rft.jtitle=Clinical+lymphoma%2C+myeloma+and+leukemia&rft.au=Khwaja%2C+Jahanzaib&rft.au=Cwynarski%2C+Kate&rft.date=2023-09-01&rft.pub=Elsevier+Inc&rft.issn=2152-2650&rft.volume=23&rft.spage=S119&rft.epage=S122&rft_id=info:doi/10.1016%2FS2152-2650%2823%2900334-8&rft.externalDocID=S2152265023003348 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2152-2650&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2152-2650&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2152-2650&client=summon |